Assessing 10x Genomics (TXG) Valuation After STELA Partnership And Ongoing Cathie Wood Buying

Why 10x Genomics Is Back in Focus

10x Genomics (TXG) is back on investor watchlists after two catalysts: its role in Bioptimus’ new STELA spatial tissue atlas, and steady share purchases by high profile fund manager Cathie Wood.

See our latest analysis for 10x Genomics.

The recent partnership on the STELA initiative and continued buying from Cathie Wood have arrived while the share price sits at US$20.43, with a 90 day share price return of 23.89% and a 1 year total shareholder return of 117.11%, although the 3 and 5 year total shareholder returns remain deeply negative.

If you are looking beyond 10x Genomics for other AI driven growth ideas in adjacent areas like life sciences and tools, it could be worth scanning 36 healthcare AI stocks

With the stock near US$20.43, a large 1 year rebound and still weak 3 and 5 year returns create a clear tension: are you seeing an undervalued genomics platform, or a story where future growth is already priced in?

Most Popular Narrative: 1% Overvalued

With 10x Genomics closing at $20.43 and the most followed fair value estimate sitting at $20.14, the current price lines up closely with that narrative while still asking you to judge some ambitious assumptions.

Global investment in genomics, including collaborations like the TISHUMAP initiative and large-scale AI-driven studies using 10x platforms, is increasing the customer base and creating new high-throughput, high-complexity data requirements, which 10x is well positioned to supply, driving expanded total addressable market and future revenue upside.

Read the complete narrative.

Curious how this story turns cautious revenue growth, a future margin lift and a premium earnings multiple into that fair value line? The key hinges on how fast the platform scales, how much profitability improves and what multiple investors might accept in a few years.

Result: Fair Value of $20.14 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh softer academic demand and instrument pricing pressure. These factors could limit how quickly those product wins translate into stronger fundamentals.

Find out about the key risks to this 10x Genomics narrative.

Another Way To Look At Value

While the analyst narrative has 10x Genomics at roughly 1% over its $20.14 fair value, our DCF model points in the other direction. On those cash flow assumptions, TXG at $20.43 trades about 38% below an estimated value of $32.79, which raises a different question for you to solve.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out 10x Genomics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 61 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With that mix of optimism and concern in mind, this is a moment to look at the numbers yourself and move quickly to shape your own view with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you miss useful context and potential opportunities. Use targeted stock lists to compare different profiles and sharpen your next move.

• Spot potential value opportunities early by checking companies that appear mispriced on fundamentals in the 61 high quality undervalued stocks.
• Build a sturdier core for your portfolio by scanning companies highlighted in the solid balance sheet and fundamentals stocks screener (39 results).
• Add some lesser known names to your watchlist by reviewing the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com